Edition:
United States

Molecular Medicine SpA (MLMD.MI)

MLMD.MI on Milan Stock Exchange

0.52EUR
23 Feb 2018
Change (% chg)

€-0.00 (-0.38%)
Prev Close
€0.53
Open
€0.53
Day's High
€0.53
Day's Low
€0.52
Volume
2,122,598
Avg. Vol
6,533,041
52-wk High
€0.60
52-wk Low
€0.40

Latest Key Developments (Source: Significant Developments)

Molmed: Dompé Exercises Option To Start Zalmoxis In Switzerland, Turkey And Australia
Thursday, 8 Feb 2018 10:53am EST 

Feb 8 (Reuters) - MOLMED SPA ::DOMPÉ EXERCISES OPTION TO ENTER MARKETS IN SWITZERLAND, TURKEY AND AUSTRALIA TO SELL ZALMOXIS.  Full Article

MolMed: Zalmoxis Can Be Reimbursed In Germany For EUR 163,900 Per Infusion
Tuesday, 16 Jan 2018 01:50am EST 

Jan 16 (Reuters) - MOLECULAR MEDICINE SPA ::SAYS THAT AS OF JAN 15 ZALMOXIS CAN BE PRESCRIBED AND REIMBURSED IN GERMANY AT THE PRICE OF EUR 163,900 PER INFUSION.APPROVED DOSAGE FORESEES ONE OR MORE INFUSIONS, UP TO A MAXIMUM OF FOUR, TILL IMMUNE-RECONSTITUTION IS ACHIEVED.MOLMED WILL BE RESPONSIBLE FOR THE PRODUCTION AND SUPPLY OF ZALMOXIS, WHILE DOMPÉ FARMACEUTICI WILL CONDUCT ACTIVITIES AIMED AT MARKETING THE THERAPY IN GERMANY.DOMPÉ WILL PAY MOLMED A PURCHASE PRICE PROPORTIONAL TO THE REIMBURSED PRICE OF THE PRODUCT.  Full Article

Molmed Q3 net loss narrows to EUR 1.6‍​ mln
Monday, 6 Nov 2017 12:00pm EST 

Nov 6 (Reuters) - MOLECULAR MEDICINE SPA ::Q3 OPERATING REVENUE EUR ‍​6.2 MILLION VERSUS EUR 3.7 MILLION YEAR AGO.Q3 NET LOSS EUR 1.6‍​ MILLION VERSUS LOSS EUR 5.9 MILLION YEAR AGO.  Full Article

Molmed submits utilization request for third tranche of share capital increase
Thursday, 21 Sep 2017 03:50pm EDT 

Sept 21 (Reuters) - Molmed Spa -:SUBMITTED UTILIZATION REQUEST FOR THIRD TRANCHE OF SHARE CAPITAL INCREASE TO BE RESERVED TO SOCIETE GENERALE AS PER SEF AGREEMENT.SUBSCRIPTION PRICE OF THIRD TRANCHE SHARES EQUAL TO EURO 0.4173/SHARE DETERMINED IN 3 TRADING DAYS FOLLOWING SUBMISSION OF REQUEST BY CO.SG CONFIRMED TO SUBSCRIBE FOR ABOUT 9 MILLION ORDINARY SHARES OF THIRD TRANCHE, CORRESPONDING TO 2.025% OF SHARE CAPITAL OF CO, FOR EURO 3.8 MILLION.  Full Article

Molmed completes second tranche of share capital increase reserved to Societe Generale
Tuesday, 8 Aug 2017 11:50am EDT 

Aug 8 (Reuters) - MOLMED SPA ::SECOND TRANCHE OF SHARE CAPITAL INCREASE RESERVED TO SOCIETE GENERALE PURSUANT TO “SEF - STANDBY EQUITY FACILITY” AGREEMENT COMPLETED.  Full Article

Molmed H1 net loss shrinks to EUR 6.5 million
Friday, 28 Jul 2017 02:59am EDT 

July 28 (Reuters) - MOLECULAR MEDICINE SPA ::REPORTED ON THURSDAY H1 OPERATING REVENUE EUR 9.8 MILLION VERSUS 10.2 MILLION A YEAR AGO.H1 NET LOSS EUR 6.5 MILLION VERSUS LOSS EUR 8.4 MILLION A YEAR AGO.  Full Article

Molmed signs development and production agreement with Cellectis
Thursday, 27 Jul 2017 01:18am EDT 

July 27 (Reuters) - MOLMED SPA ::SIGNS WITH CELLECTIS AGREEMENT FOR DEVELOPMENT AND PRODUCTION IN THE FIELD OF ALLOGENEIC CAR-T PRODUCTS.  Full Article

Molmed signs strategic commercialization and supply agreements with Dompe
Wednesday, 26 Jul 2017 01:25am EDT 

July 26 (Reuters) - MOLMED SPA ::MOLMED AND DOMPE SIGN 15-YEAR LICENSE AND DISTRIBUTION AGREEMENT FOR SUPPLY OF ZALMOXIS IN EUROPE.DOMPE TO CONDUCT ALL ACTIVITIES AIMED AT PROMOTING, MARKETING, EXPLOITING, DISTRIBUTING AND SELLING ZALMOXIS IN EUROPEAN ECONOMIC AREA AND AN OPTION RIGHT FOR SWITZERLAND, TURKEY AND AUSTRALIA.MOLMED AND DOMPE ALSO SIGN MANUFACTURING AND SUPPLY AGREMENT UNDER WHICH MOLMED WILL BE RESPONSIBLE FOR PRODUCTION, SUPPLY AND DELIVERY OF ZALMOXIS TO THE FINAL USERS IN ALL COUNTRIES.DOMPE TO RECOGNIZE A PURCHASE PRICE PROPORTIONAL TO THE REIMBURSED PRICE OF THE PRODUCT.MOLMED TO RECEIVE UP TO EUR 43.5 MILLION, OF WHICH UP TO EUR 12.5 MILLION AS CONTRIBUTIONS IN THE 2017-2020 TIMEFRAME.MOLMED TO RECEIVE UP TO EUR 31 MILLION AS SALES MILESTONES, DEPENDING ON ANNUAL NET SALES GENERATED IN EACH COUNTRY COVERED BY THE AGREEMENT.  Full Article

Molmed and TTY Biopharm enter into exclusive agreement to commercialise Zalmoxis in certain Asian territories
Friday, 30 Jun 2017 01:35am EDT 

June 30 (Reuters) - MOLMED SPA : :MOLMED AND TTY BIOPHARM ENTER INTO AN EXCLUSIVE AGREEMENT TO COMMERCIALISE ZALMOXIS® IN CERTAIN ASIAN TERRITORIES.SAYS SIGNED AN EXCLUSIVE LICENSE AND DISTRIBUTION AGREEMENT WHICH DEFINES ALL TERMS AND CONDITIONS TO IMPORT, USE, MARKET, SELL AND/OR DISTRIBUTE ZALMOXIS FOR THE TREATMENT OF HAEMATOLOGICAL MALIGNANCIES IN TAIWAN, HONG KONG, SINGAPORE, THAILAND, PHILIPPINES, VIETNAM AND MALAYSIA.MOLMED WILL RECEIVE AN UPFRONT PAYMENT, POTENTIAL REGULATORY AND SALES MILESTONE PAYMENTS UP TO EURO 13.5 MILLION.MOLMED WILL RECEIVE AS WELL ROYALTY PAYMENTS IN RANGE OF 10% TO 20% ON ANNUAL NET SALES GENERATED IN EACH COUNTRY COVERED BY THE AGREEMENT.  Full Article

MolMed and Megapharm enter into a license and distribution agreement for Zalmoxis in Israel
Friday, 28 Apr 2017 11:54am EDT 

April 28 (Reuters) - MolMed SpA ::Molmed and Megapharm sign licensing and distribution contract for Zalmoxis in Israel.Zalmoxis will be distributed and marketed by Megapharm, once approved by the Israeli Ministry of Health (MOH) and included in the Israeli national health basket of drugs by the MOH.Zalmoxis is a cell-based therapy enabling bone marrow transplants from partially compatible donors currently in Phase III in high-risk acute leukemia .  Full Article

BRIEF-Molmed: Dompé Exercises Option To Start Zalmoxis In Switzerland, Turkey And Australia

* DOMPÉ EXERCISES OPTION TO ENTER MARKETS IN SWITZERLAND, TURKEY AND AUSTRALIA TO SELL ZALMOXIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)